$AIML: What to Watch for in 2026

$AIML reads less like a one-time catalyst story and more like a staged build toward commercialization.

Key milestones ahead

First paid contracts in Q2
CardioYield FDA 510(k) submission in Q2–Q3
10+ paying clinics targeted through the DPC channel in Q3
Infrastructure revenue catalyst in Q3–Q4
Jamaica nationwide rollout in H2

The roadmap is still in prove-it mode, but the milestones are clear. Does the re-rating start with first meaningful revenue, or only once clinic adoption becomes repeatable? What would make you revisit this?

This is sponsored content. Investors should conduct their own due diligence and consult a qualified financial advisor before making any investment decisions.